Persistence of IgG response to SARS-CoV-2
Participants are tested on a monthly basis for the presence of SARS-CoV-2 with quantitative RT-PCR (RT-qPCR) and for antibodies targeting S1 (spike subunit 1) protein with a commercial semi-quantitative ELISA (Euroimmun IgG; Medizinische Labordiagnostika, Lübeck, Germany), using a stringent manufac...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2021-02, Vol.21 (2), p.163-164 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 164 |
|---|---|
| container_issue | 2 |
| container_start_page | 163 |
| container_title | The Lancet infectious diseases |
| container_volume | 21 |
| creator | Duysburgh, Els Mortgat, Laure Barbezange, Cyril Dierick, Katelijne Fischer, Natalie Heyndrickx, Leo Hutse, Veronik Thomas, Isabelle Van Gucht, Steven Vuylsteke, Bea Ariën, Kevin K Desombere, Isabelle |
| description | Participants are tested on a monthly basis for the presence of SARS-CoV-2 with quantitative RT-PCR (RT-qPCR) and for antibodies targeting S1 (spike subunit 1) protein with a commercial semi-quantitative ELISA (Euroimmun IgG; Medizinische Labordiagnostika, Lübeck, Germany), using a stringent manufacturer-defined cut-off for having a positive test result (ratio ≥1·1; NCT04373889).6 By the end of September, 2020, seven rounds of testing had been done. To assess the longevity of the humoral immune response, we recorded the duration of the presence of detectable IgG in the serum of health-care workers who were seropositive for SARS-CoV-2. Of note, of the 13 individuals with no detectable neutralising antibodies, eight had weak neutralising antibody titres (NT50 55–100) and five had no measurable neutralising antibody titres from the start. Since antibodies specific for SARS-CoV-2 were only assessed for S1 protein, and because S1-specific cross-reactivity of prepandemic serum samples from patients infected with common cold human coronaviruses has been described,7,8 an explanation could be that these five individuals are false-positive for SARS-CoV-2 antibodies. |
| doi_str_mv | 10.1016/S1473-3099(20)30943-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7833610</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309920309439</els_id><sourcerecordid>2471538819</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-8a3691c37c9fbc86a65df3210d40025a6e52fc79e985a5560d7339a2049ecfcd3</originalsourceid><addsrcrecordid>eNqFkUtLAzEUhYMo1tdPUAbctIvRPGcmG0WKj0JBseo2xMydGplOajIV_PemnSrqxtW95H45yT0HoUOCTwgm2emE8JylDEvZp3gQK2ep3EA78ZinnIt8c9V3SA_thvCKMckJ5tuoxxjjhFC-gwZ34IMNLTQGElclo-l14iHMXRMgaV0yubifpEP3lNJ9tFXpOsDBuu6hx6vLh-FNOr69Hg0vxqnhUrRpoVkmiWG5kdWzKTKdibJilOCSY0yFzkDQyuQSZCG0EBkuc8akpphLMJUp2R4663Tni-cZlAaa1utazb2daf-hnLbq96SxL2rq3lVeMJYRHAX6awHv3hYQWjWzwUBd6wbcIijKcyJYURAZ0eM_6Ktb-CauF6mCCM4KziMlOsp4F4KH6vszBKtlGGoVhlo6rShWqzDUUv3o5ybft77cj8B5B0D0892CV8HYZRKl9WBaVTr7zxOfqLGWoA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2481543844</pqid></control><display><type>article</type><title>Persistence of IgG response to SARS-CoV-2</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Duysburgh, Els ; Mortgat, Laure ; Barbezange, Cyril ; Dierick, Katelijne ; Fischer, Natalie ; Heyndrickx, Leo ; Hutse, Veronik ; Thomas, Isabelle ; Van Gucht, Steven ; Vuylsteke, Bea ; Ariën, Kevin K ; Desombere, Isabelle</creator><creatorcontrib>Duysburgh, Els ; Mortgat, Laure ; Barbezange, Cyril ; Dierick, Katelijne ; Fischer, Natalie ; Heyndrickx, Leo ; Hutse, Veronik ; Thomas, Isabelle ; Van Gucht, Steven ; Vuylsteke, Bea ; Ariën, Kevin K ; Desombere, Isabelle</creatorcontrib><description>Participants are tested on a monthly basis for the presence of SARS-CoV-2 with quantitative RT-PCR (RT-qPCR) and for antibodies targeting S1 (spike subunit 1) protein with a commercial semi-quantitative ELISA (Euroimmun IgG; Medizinische Labordiagnostika, Lübeck, Germany), using a stringent manufacturer-defined cut-off for having a positive test result (ratio ≥1·1; NCT04373889).6 By the end of September, 2020, seven rounds of testing had been done. To assess the longevity of the humoral immune response, we recorded the duration of the presence of detectable IgG in the serum of health-care workers who were seropositive for SARS-CoV-2. Of note, of the 13 individuals with no detectable neutralising antibodies, eight had weak neutralising antibody titres (NT50 55–100) and five had no measurable neutralising antibody titres from the start. Since antibodies specific for SARS-CoV-2 were only assessed for S1 protein, and because S1-specific cross-reactivity of prepandemic serum samples from patients infected with common cold human coronaviruses has been described,7,8 an explanation could be that these five individuals are false-positive for SARS-CoV-2 antibodies.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(20)30943-9</identifier><identifier>PMID: 33341124</identifier><language>eng</language><publisher>United States: Elsevier Ltd</publisher><subject>Antibodies ; Antibodies, Neutralizing - immunology ; Antibodies, Viral - immunology ; Asymptomatic ; Comment ; Common cold ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - epidemiology ; COVID-19 - immunology ; COVID-19 - virology ; Cross-reactivity ; Health care ; Health Personnel ; Host-Pathogen Interactions - immunology ; Humans ; Immune response ; Immune response (humoral) ; Immunoglobulin G ; Immunoglobulin G - immunology ; Infections ; Infectious diseases ; Polymerase chain reaction ; Proteins ; SARS-CoV-2 - genetics ; SARS-CoV-2 - immunology ; Seroepidemiologic Studies ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>The Lancet infectious diseases, 2021-02, Vol.21 (2), p.163-164</ispartof><rights>2021 Elsevier Ltd</rights><rights>2021. Elsevier Ltd</rights><rights>2020 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-8a3691c37c9fbc86a65df3210d40025a6e52fc79e985a5560d7339a2049ecfcd3</citedby><cites>FETCH-LOGICAL-c495t-8a3691c37c9fbc86a65df3210d40025a6e52fc79e985a5560d7339a2049ecfcd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309920309439$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33341124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Duysburgh, Els</creatorcontrib><creatorcontrib>Mortgat, Laure</creatorcontrib><creatorcontrib>Barbezange, Cyril</creatorcontrib><creatorcontrib>Dierick, Katelijne</creatorcontrib><creatorcontrib>Fischer, Natalie</creatorcontrib><creatorcontrib>Heyndrickx, Leo</creatorcontrib><creatorcontrib>Hutse, Veronik</creatorcontrib><creatorcontrib>Thomas, Isabelle</creatorcontrib><creatorcontrib>Van Gucht, Steven</creatorcontrib><creatorcontrib>Vuylsteke, Bea</creatorcontrib><creatorcontrib>Ariën, Kevin K</creatorcontrib><creatorcontrib>Desombere, Isabelle</creatorcontrib><title>Persistence of IgG response to SARS-CoV-2</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Participants are tested on a monthly basis for the presence of SARS-CoV-2 with quantitative RT-PCR (RT-qPCR) and for antibodies targeting S1 (spike subunit 1) protein with a commercial semi-quantitative ELISA (Euroimmun IgG; Medizinische Labordiagnostika, Lübeck, Germany), using a stringent manufacturer-defined cut-off for having a positive test result (ratio ≥1·1; NCT04373889).6 By the end of September, 2020, seven rounds of testing had been done. To assess the longevity of the humoral immune response, we recorded the duration of the presence of detectable IgG in the serum of health-care workers who were seropositive for SARS-CoV-2. Of note, of the 13 individuals with no detectable neutralising antibodies, eight had weak neutralising antibody titres (NT50 55–100) and five had no measurable neutralising antibody titres from the start. Since antibodies specific for SARS-CoV-2 were only assessed for S1 protein, and because S1-specific cross-reactivity of prepandemic serum samples from patients infected with common cold human coronaviruses has been described,7,8 an explanation could be that these five individuals are false-positive for SARS-CoV-2 antibodies.</description><subject>Antibodies</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibodies, Viral - immunology</subject><subject>Asymptomatic</subject><subject>Comment</subject><subject>Common cold</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 - virology</subject><subject>Cross-reactivity</subject><subject>Health care</subject><subject>Health Personnel</subject><subject>Host-Pathogen Interactions - immunology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune response (humoral)</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulin G - immunology</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Polymerase chain reaction</subject><subject>Proteins</subject><subject>SARS-CoV-2 - genetics</subject><subject>SARS-CoV-2 - immunology</subject><subject>Seroepidemiologic Studies</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkUtLAzEUhYMo1tdPUAbctIvRPGcmG0WKj0JBseo2xMydGplOajIV_PemnSrqxtW95H45yT0HoUOCTwgm2emE8JylDEvZp3gQK2ep3EA78ZinnIt8c9V3SA_thvCKMckJ5tuoxxjjhFC-gwZ34IMNLTQGElclo-l14iHMXRMgaV0yubifpEP3lNJ9tFXpOsDBuu6hx6vLh-FNOr69Hg0vxqnhUrRpoVkmiWG5kdWzKTKdibJilOCSY0yFzkDQyuQSZCG0EBkuc8akpphLMJUp2R4663Tni-cZlAaa1utazb2daf-hnLbq96SxL2rq3lVeMJYRHAX6awHv3hYQWjWzwUBd6wbcIijKcyJYURAZ0eM_6Ktb-CauF6mCCM4KziMlOsp4F4KH6vszBKtlGGoVhlo6rShWqzDUUv3o5ybft77cj8B5B0D0892CV8HYZRKl9WBaVTr7zxOfqLGWoA</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Duysburgh, Els</creator><creator>Mortgat, Laure</creator><creator>Barbezange, Cyril</creator><creator>Dierick, Katelijne</creator><creator>Fischer, Natalie</creator><creator>Heyndrickx, Leo</creator><creator>Hutse, Veronik</creator><creator>Thomas, Isabelle</creator><creator>Van Gucht, Steven</creator><creator>Vuylsteke, Bea</creator><creator>Ariën, Kevin K</creator><creator>Desombere, Isabelle</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210201</creationdate><title>Persistence of IgG response to SARS-CoV-2</title><author>Duysburgh, Els ; Mortgat, Laure ; Barbezange, Cyril ; Dierick, Katelijne ; Fischer, Natalie ; Heyndrickx, Leo ; Hutse, Veronik ; Thomas, Isabelle ; Van Gucht, Steven ; Vuylsteke, Bea ; Ariën, Kevin K ; Desombere, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-8a3691c37c9fbc86a65df3210d40025a6e52fc79e985a5560d7339a2049ecfcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibodies, Viral - immunology</topic><topic>Asymptomatic</topic><topic>Comment</topic><topic>Common cold</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 - virology</topic><topic>Cross-reactivity</topic><topic>Health care</topic><topic>Health Personnel</topic><topic>Host-Pathogen Interactions - immunology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune response (humoral)</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulin G - immunology</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Polymerase chain reaction</topic><topic>Proteins</topic><topic>SARS-CoV-2 - genetics</topic><topic>SARS-CoV-2 - immunology</topic><topic>Seroepidemiologic Studies</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Duysburgh, Els</creatorcontrib><creatorcontrib>Mortgat, Laure</creatorcontrib><creatorcontrib>Barbezange, Cyril</creatorcontrib><creatorcontrib>Dierick, Katelijne</creatorcontrib><creatorcontrib>Fischer, Natalie</creatorcontrib><creatorcontrib>Heyndrickx, Leo</creatorcontrib><creatorcontrib>Hutse, Veronik</creatorcontrib><creatorcontrib>Thomas, Isabelle</creatorcontrib><creatorcontrib>Van Gucht, Steven</creatorcontrib><creatorcontrib>Vuylsteke, Bea</creatorcontrib><creatorcontrib>Ariën, Kevin K</creatorcontrib><creatorcontrib>Desombere, Isabelle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Duysburgh, Els</au><au>Mortgat, Laure</au><au>Barbezange, Cyril</au><au>Dierick, Katelijne</au><au>Fischer, Natalie</au><au>Heyndrickx, Leo</au><au>Hutse, Veronik</au><au>Thomas, Isabelle</au><au>Van Gucht, Steven</au><au>Vuylsteke, Bea</au><au>Ariën, Kevin K</au><au>Desombere, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Persistence of IgG response to SARS-CoV-2</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>21</volume><issue>2</issue><spage>163</spage><epage>164</epage><pages>163-164</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><abstract>Participants are tested on a monthly basis for the presence of SARS-CoV-2 with quantitative RT-PCR (RT-qPCR) and for antibodies targeting S1 (spike subunit 1) protein with a commercial semi-quantitative ELISA (Euroimmun IgG; Medizinische Labordiagnostika, Lübeck, Germany), using a stringent manufacturer-defined cut-off for having a positive test result (ratio ≥1·1; NCT04373889).6 By the end of September, 2020, seven rounds of testing had been done. To assess the longevity of the humoral immune response, we recorded the duration of the presence of detectable IgG in the serum of health-care workers who were seropositive for SARS-CoV-2. Of note, of the 13 individuals with no detectable neutralising antibodies, eight had weak neutralising antibody titres (NT50 55–100) and five had no measurable neutralising antibody titres from the start. Since antibodies specific for SARS-CoV-2 were only assessed for S1 protein, and because S1-specific cross-reactivity of prepandemic serum samples from patients infected with common cold human coronaviruses has been described,7,8 an explanation could be that these five individuals are false-positive for SARS-CoV-2 antibodies.</abstract><cop>United States</cop><pub>Elsevier Ltd</pub><pmid>33341124</pmid><doi>10.1016/S1473-3099(20)30943-9</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2021-02, Vol.21 (2), p.163-164 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7833610 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Asymptomatic Comment Common cold Coronaviruses COVID-19 COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - immunology COVID-19 - virology Cross-reactivity Health care Health Personnel Host-Pathogen Interactions - immunology Humans Immune response Immune response (humoral) Immunoglobulin G Immunoglobulin G - immunology Infections Infectious diseases Polymerase chain reaction Proteins SARS-CoV-2 - genetics SARS-CoV-2 - immunology Seroepidemiologic Studies Severe acute respiratory syndrome coronavirus 2 |
| title | Persistence of IgG response to SARS-CoV-2 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A47%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Persistence%20of%20IgG%20response%20to%20SARS-CoV-2&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Duysburgh,%20Els&rft.date=2021-02-01&rft.volume=21&rft.issue=2&rft.spage=163&rft.epage=164&rft.pages=163-164&rft.issn=1473-3099&rft.eissn=1474-4457&rft_id=info:doi/10.1016/S1473-3099(20)30943-9&rft_dat=%3Cproquest_pubme%3E2471538819%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2481543844&rft_id=info:pmid/33341124&rft_els_id=S1473309920309439&rfr_iscdi=true |